AnaptysBio Inc (ANAB)
19.94
-1.74
(-8.03%)
USD |
NASDAQ |
Nov 04, 16:00
19.67
-0.27
(-1.35%)
After-Hours: 20:00
AnaptysBio Net Income (Annual): -163.62M for Dec. 31, 2023
Net Income (Annual) Chart
Historical Net Income (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | -163.62M |
| December 31, 2022 | -128.72M |
| December 31, 2021 | -57.80M |
| December 31, 2020 | -19.93M |
| December 31, 2019 | -97.34M |
| December 31, 2018 | -61.66M |
| Date | Value |
|---|---|
| December 31, 2017 | -30.07M |
| December 31, 2016 | -4.259M |
| December 31, 2015 | -5.405M |
| December 31, 2014 | 3.532M |
| December 31, 2013 | -5.545M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Annual) Range, Past 5 Years
-163.62M
Minimum
2023
-19.93M
Maximum
2020
-93.48M
Average
-97.34M
Median
2019
Net Income (Annual) Benchmarks
| Regeneron Pharmaceuticals Inc | 3.954B |
| Ligand Pharmaceuticals Inc | 52.15M |
| Agios Pharmaceuticals Inc | -352.09M |
| ADMA Biologics Inc | -28.24M |
| Black Diamond Therapeutics Inc | -82.44M |